Journey Medical Patent-Cliff Exposure & CMS Drug Spending Portfolio
Journey Medical (US): 6 reconciled FDA prescription therapies (14.7% 2025 to 2030 cliff risk), $2.9M 2024 CMS Part D & Medicaid spend, and $1,298 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 6 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 14.7% |
| Primary Portfolio LOE Date | 2030-01-01 |
| 2024 CMS Total Public Spend | $2.9M |
| 2024 Medicare Part D Spend | $2.9M |
| 2024 Medicaid Spend | $0 |
| California HCAI SB 17 Filings | Specialty launch notice ($1,298 intro WAC) |